Search

Displaying results 1501 - 1510 of 7604 in total
  1. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.

    Synonyms: N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
  2. Drug

    Hydroxycitronellal

    go.drugbank.com/drugs/DB14187
    Approved

    Hydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain … Sensitivity to hydroxycitronellal may be identified with a clinical patch test.

  3. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc. … (NV).

  4. Drug

    Olodaterol

    go.drugbank.com/drugs/DB09080
    ApprovedInvestigational

    Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. … Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs.

    Categories: Agents to Treat Airway Disease
  5. Drug

    Aripiprazole

    go.drugbank.com/drugs/DB01238
    ApprovedInvestigational

    [L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.[L6136]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Nb-aripiprazole
  6. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.

  7. Drug

    Cinacalcet

    go.drugbank.com/drugs/DB01012
    ApprovedInvestigational

    Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. … It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

    Synonyms: (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine, N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
  8. Drug

    Beclomethasone dipropionate

    go.drugbank.com/drugs/DB00394
    ApprovedInvestigational

    to reduce symptoms. … [A180010] Compared to earlier corticosteroids such as [dexamethasone] and [prednisolone], beclomethasone dipropionate is reported to be less irritating to the nasal mucosa with a longer duration of action

    Mixtures: FORMODUAL N. 200/6UG, FORMODUAL N. 200/6UGCategories: Agents to Treat Airway Disease
  9. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … [L12951] Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.[L12945]

  10. Drug

    Etodolac

    go.drugbank.com/drugs/DB00749
    ApprovedInvestigationalVet approved

    Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. … Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic